Cosmos Health Inc. COSM PHARMA

Q: What is the current share price of Cosmos Health Inc. (COSM)?

As of 2026-09-19 21:16 PDT, Cosmos Health Inc. (COSM) trades at $0.27 on NasdaqCM. Its 52-week range is $0.17 to $1.25.

Q: What is the market capitalisation of COSM?

Cosmos Health Inc. (COSM) has a market capitalisation of $27.17M on NasdaqCM.

Q: What is the P/E ratio of COSM?

COSM trades at a trailing price-to-earnings (P/E) ratio of -0.40. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.00.

Q: What is the return on equity (ROE) of COSM?

COSM has a return on equity (ROE) of -104.00%. Its return on capital employed (ROCE) is -61.40%.

Q: Is COSM a good stock to buy?

This page provides a data-driven analysis of Cosmos Health Inc. (COSM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Distribution · Greece

https://www.cosmoshealthinc.com

Company Profile ↓

$0.27

-66.41% 1Y

Mkt Cap$27.17M

P/E-0.40

P/B1.00

52W High$1.25

52W Low$0.17

Book Value$0.26

EPS (TTM)$-0.67

Company Overview

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand. It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 42.9% CAGR over the past five years.

Recent Developments

Dec 2025 Revenue of $65.27M (+19.9% YoY); net profit $-19.14M.
Trailing 12 Months Year-on-year growth — revenue +28.8%.
5-Year Trend Long-term compounding — revenue CAGR 42.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	42.87%
1 Year:	28.80%

Stock Price Performance

1 Year:	-66.41%
6 Months:	-29.77%
3 Months:	+17.57%
1 Month:	+16.05%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 9% of range

$0.17 $1.25

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMABelow
RSI (14)63.40 · Neutral

Price Performance

1M+16.05%

3M+17.57%

6M-29.77%

1Y-66.41%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 42.9% over 5 years.

CONS

Trading 78.4% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.40

Industry PE

24.83

Forward P/E

3.86

PEG Ratio

Book Value

$0.26

Price to Book

1.00

P/S

0.35

EV/EBITDA

-2.46

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

42.87%

Profit 5Y

Revenue (YoY)

28.80%

Earnings (YoY)

Profitability & Returns

ROCE

-61.40%

ROE

-104.00%

ROA

-18.42%

Profit Margin

-33.08%

Op Margin

-15.41%

Gross Margin

10.27%

EPS (Latest Qtr)

$-0.06

EPS (TTM)

$-0.67

Balance Sheet & Liquidity

Debt/Equity

0.77

Quick Ratio

0.67

Current Ratio

1.05

Debt

$15.98M

Total Assets

$62.37M

Current Assets

$38.39M

Working Capital

$116.41K

Ownership

Promoter Holding

21.68%

Chg in Prom Hold

-14.71%

FII / Inst Holding

3.67%

Chg in FII Hold

-1.45%

Financial Snapshot

Enterprise Value

$27.17M

Total Revenue (TTM)

$73.73M

EBITDA

$-16.79M

Free Cash Flow

$-10.07M

Operating Cash Flow

$-9.84M

Shares Outstanding

100.63M

Gross Margin

10.27%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	COSM Cosmos Health Inc. PHARMA	0.27	-0.40	$27.17M	0.00%	-61.40%	-104.00%	42.87%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Apr 2013	Jun 2013	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	781.06K	1.23M	5.78M	-	-	-	1.14M	955.89K	1.41M	4.12M	6.11M	9.55M	11.97M	8.86M	8.51M	9.68M	8.51M	9.69M	11.93M	12.82M	14.35M	11.62M	14.85M	13.60M	13.07M	13.21M	12.02M	12.35M	12.36M	12.82M	14.58M	13.21M	12.41M	13.71M	14.75M	17.11M	17.93M
Gross Profit	-	-	-	-	-	-	-	-	-	87.68K	81.71K	144.95K	363.69K	480.10K	774.81K	610.00K	702.33K	793.72K	626.16K	468.99K	799.77K	1.19M	2.35M	2.40M	1.00M	2.04M	2.35M	1.89M	1.85M	1.78M	957.08K	946.83K	1.21M	1.33M	767.25K	1.21M	2.05M	1.16M	2.60M	1.38M
Operating Income	-58.04K	493.72K	-79.34K	707.88K	1.07M	5.59M	-84.28K	-109.80K	-75.15K	-41.02K	-86.93K	-30.97K	-1.98M	-796.64K	16.45K	-149.55K	-78.78K	41.49K	-173.74K	-525.89K	-116.56K	225.56K	986.31K	1.08M	-1.73M	-1.38M	-914.55K	242.25K	-74.36K	-344.11K	-2.65M	-2.58M	-3.02M	-1.84M	-2.50M	-2.24M	-833.14K	-2.65M	-1.82M	-2.18M
Net Income	-58.04K	-	-79.83K	614.22K	928.28K	4.75M	-108.65K	-132.62K	-100.39K	-69.11K	-114.08K	-94.61K	-2.03M	-839.62K	-198.17K	-3.06M	782.39K	3.21M	-217.17K	-1.54M	-1.63M	-483.31K	1.38M	757.87K	-2.17M	-2.38M	-1.94M	203.35K	-1.24M	-1.97M	-459.86K	-981.53K	-3.35M	-1.87M	-2.59M	-8.38M	-818.10K	-2.83M	-5.35M	-2.81M
Diluted EPS	-	0.00	0.00	0.00	0.01	0.04	0.00	0.00	0.00	0.00	0.00	0.00	-	-0.07	-0.02	-0.24	0.06	0.24	-0.02	-0.12	-0.12	-0.04	0.10	0.06	-0.14	-0.15	-0.11	-7.86	-23.37	-1.93	-0.04	-0.09	-0.27	-0.11	-0.15	-0.45	-0.03	-0.10	-0.17	-0.06
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	15.63K	74.64K	18.34K	0

Profit & Loss (Annual)

Figures in USD.

Metric	Jul 2010	Jul 2011	Jul 2012	Dec 2012	Jul 2013	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	902.37K	7.64M	533.80K	6.76M	30.01M	37.08M	39.68M	55.41M	56.24M	50.35M	53.38M	54.43M	65.27M
Gross Profit	-	-	-	-	-	-	7.64M	48.99K	601.04K	1.96M	2.41M	3.66M	8.06M	8.33M	5.96M	4.35M	4.31M	7.90M
Operating Income	-	-	-330.59K	-455	-344.54K	288.71K	7.12M	-442.46K	-202.51K	-4.87M	-1.23M	-255.81K	2.71M	-4.53M	-7.47M	-21.83M	-15.54M	-16.70M
Net Income	-3.79M	-169.25K	-330.59K	-455	-344.54K	246.59K	6.04M	-6.69M	-601.00K	-6.21M	-9.06M	-3.30M	820.79K	-7.96M	-13.83M	-18.54M	-16.18M	-19.14M
Diluted EPS	-	-	-	0.00	-	0.00	0.05	-0.05	80,741.00	-0.49	-0.68	-0.25	0.06	-23.74	-33.16	-2.15	-1.17	-0.63
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	164.86K	533.29K	519.36K

Balance Sheet (Annual)

Figures in USD.

Metric	Jul 2009	Jul 2010	Jul 2011	Dec 2011	Jul 2012	Dec 2012	Jul 2013	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Jan 2018	Dec 2018	Dec 2019	Jan 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	40	-	18.84K	867.05K	7.23M	657.62K	3.12M	10.68M	-	20.69M	23.88M	-	43.84M	-	68.04M	66.01M	54.31M	65.48M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56.37M	36.61M	25.46M	38.39M
Cash & Equivalents	-	-	15.24K	-	40	-	18.84K	864.49K	446.60K	198.05K	716.59K	782.85K	-	864.34K	38.54K	-	628.39K	-	20.75M	3.83M	315.11K	715.67K
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.45M	4.79M	4.36M	5.78M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23.69M	19.76M	13.48M	19.63M
Total Liabilities	-	-	-	-	213.16K	1.40K	358.67K	920.73K	1.76M	1.91M	4.87M	13.70M	-	24.01M	30.34M	-	48.01M	-	28.38M	29.97M	29.78M	47.05M
Current Liabilities	-	-	-	-	-	-	-	-	1.76M	1.91M	4.87M	13.70M	-	22.27M	28.24M	-	34.29M	-	21.75M	24.32M	25.76M	38.27M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	145.50K	0	-	10.77M	-	2.86M	3.04M	1.56M	5.85M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.03M	12.42M	11.82M	19.97M
Total Equity	-4.60K	-17.48K	-4.76K	-917	-213.12K	-1.40K	-339.83K	-53.68K	5.47M	-1.25M	-1.75M	-3.03M	-3.03M	-3.32M	-6.46M	-6.46M	-4.16M	-	39.66M	36.04M	24.53M	18.42M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.61M	15.98M	23.69M	41.15M

Cash Flows (Annual)

Figures in USD.

Metric	Jul 2012	Dec 2012	Jul 2013	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-66.06K	31	-72.94K	831.40K	6.53M	-497.09K	-2.13M	-8.76M	-1.56M	-4.79M	-11.50M	-	-14.87M	-15.64M	-7.72M	-8.45M
Investing Cash Flow	-	-	-	18.15K	-6.76M	-43.95K	-144.72K	-14.48K	-195.77K	588.93K	-117.74K	-	-21.50K	-13.76M	-798.27K	-2.01M
Financing Cash Flow	50.87K	917	91.73K	2.37K	504.12K	329.12K	2.74M	9.29M	1.99M	3.59M	12.46M	-	35.05M	12.69M	5.05M	14.06M
Capital Expenditure	-	-	-	-	-21.47K	-43.95K	-12.82K	-55.34K	-503.36K	-	-117.74K	-	-383.07K	-9.17M	-1.27M	-152.82K
Free Cash Flow	-	-	-	-	6.50M	-541.04K	-2.14M	-8.82M	-2.06M	-	-11.62M	-	-15.25M	-24.80M	-8.98M	-8.60M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	20.16M	-16.70M	-3.47M	3.59M
Share Buybacks	-	-	-	-	-	-	-	-	-	-	200.00K	376.86K	-	100.45K	0	-

Ratios (Annual)

Figures in %.

Metric	Jul 2010	Jul 2011	Jul 2012	Dec 2012	Jul 2013	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	100.0%	9.2%	8.9%	6.5%	6.5%	9.2%	14.5%	14.8%	11.8%	8.1%	7.9%	12.1%
Operating Margin %	-	-	-	-	-	32.0%	93.2%	-82.9%	-3.0%	-16.2%	-3.3%	-0.6%	4.9%	-8.1%	-14.8%	-40.9%	-28.6%	-25.6%
Net Margin %	-	-	-	-	-	27.3%	79.1%	-1,252.9%	-8.9%	-20.7%	-24.4%	-8.3%	1.5%	-14.2%	-27.5%	-34.7%	-29.7%	-29.3%
ROE %	21,670.6%	3,554.1%	155.1%	32.4%	101.4%	-459.3%	110.4%	536.0%	34.3%	205.1%	273.1%	51.1%	-19.7%	-	-34.9%	-51.4%	-66.0%	-103.9%
ROCE %	-	-	-	-	-	-	130.0%	35.5%	11.6%	160.9%	77.8%	5.9%	28.4%	-	-16.1%	-52.4%	-54.4%	-61.4%

Shareholding Pattern

Insiders

21.68%

Institutions

3.67%

Public Float

4.68%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	UBS Group AG	0.59%	594.46K	$188.92K
2	Vanguard Fiduciary Trust Co	0.33%	333.84K	$106.09K
3	Jane Street Group, LLC	0.29%	289.29K	$91.94K
4	Geode Capital Management, LLC	0.28%	282.09K	$89.65K
5	Blackrock Inc.	0.27%	267.80K	$85.11K
6	Vanguard Capital Management LLC	0.17%	173.97K	$55.29K
7	Northern Trust Corporation	0.05%	53.89K	$17.12K
8	State Street Corporation	0.04%	45.24K	$14.38K
9	Sassicaia Capital Advisers, LLC	0.04%	36.00K	$11.44K
10	Kestra Private Wealth Services, LLC	0.01%	13.00K	$4.13K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for COSM

Google News Sun, 06 Sep 2026

Why Did SOC, HTZ, COSM Stocks Tumble To 52-Week Lows? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNRzllLVJ1XzZSSFJnSDBWWVBwRTZMSnN6WDlLUUJSZU1YbmF4eTBxeHd2bHQ5WXhDdmNFeV93OW4tcmM2Q25rV3QxNGl4cWpMLUQ2bkQ4Tm8xVHhTRW9uV0tfUTVKLVNrZk9GYldwelphN3JCQ0tPakRpaW0yUjE3M1lRcTd2akxYYmI2ZE…

Google News hu, 03 Sep 2026

$8 million debt paid off. Cosmos Health bought back 5.1 million shares. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxORE9Ib2hDNDFZMzVHb05yUHZDZWlJcEtvWWpqc2QtbGxMUlF2M3hUMzBCTUJON1daY2NSUjlUT2hPYVZyTFhHM3MwYjcyT2g4VTFHdEZOdUtoWG9IVG9Qc3VxcUFXOF9UYUoyUThxaGg2U2pWNHNCX183VHgwUVRqSGNKSXMxekp2MmN4d3…

Google News Mon, 31 Aug 2026

$COSM stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQT2hURDl6WDJiZHZqcHYtc1RVc1l3M2J4eW9xakFMeTBpN2pxVkpkSkRuODNPdENZY0pUOGtBbWxQMmFZQmV2T1Rha3YxSG12LVkwT0tuZVQ1NklYREVUdWJxaVlMLVFzYU8zUnlRblR1QWYwdnFCS21LTmNtM28xQ3dqaUpOZGY5X3plZn…

Google News ue, 30 Jun 2026

Why Did SOC, HTZ, COSM Stocks Tumble To 52-Week Lows? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNVlBSWU50YllWZDN2Q08xY3E1bXppMjFFcmR6RklCRlNEazJYWkMwMFdwakk5NjZvVXBKVHhjdmlwWjd3bkZ3ZFNqVkpGZmF0Z1FLbmg2NVJNYlZNV2p3VURBVHpqNUl1VGYxcmpSS3pqZTRjQU9zRjl2ZXJad1R1OVkwb0ttSTdSS2wwUD…

Google News Fri, 28 Aug 2026

Cosm | shares highlights from IPS and Ecsite 2026 - Blooloop

<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTE5zUXRHbi1TLVUtd2FseDZGZ2NyQklLNmNoNmlsSVVTU0N3Xy1BVG5aTS1IbDZveHE1alBKZjdzdl9seDFnam9XMVNiRldoa1BNTVF0Sg?oc=5" target="_blank">Cosm | shares highlights from IPS and Ecsite 2026</a>…

Google News Sat, 29 Aug 2026

Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine - Fortune

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPU2tFR01HUWx1eks2bWNfdGFjXzFPb0p3a1dWeElBdnhXcFRFM3NBUDFHakRudW00cmZlZ2kzY1pZZzBmU1NUbTdkQ09YNDNDLXpZbnYycVBCRnFEOXp4bEUyWS03blIzb1A2VElPazI3Z1c2QkNvWWtCendUUjk1cTVQcmRucWlTUnpjd1…

COSM — Frequently Asked Questions

What is the current share price of Cosmos Health Inc. (COSM)?

As of 2026-09-19 21:16 PDT, Cosmos Health Inc. (COSM) trades at $0.27 on NasdaqCM. Its 52-week range is $0.17 to $1.25.

What is the market capitalisation of COSM?

Cosmos Health Inc. (COSM) has a market capitalisation of $27.17M on NasdaqCM.

What is the P/E ratio of COSM?

COSM trades at a trailing price-to-earnings (P/E) ratio of -0.40. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.00.

What is the return on equity (ROE) of COSM?

COSM has a return on equity (ROE) of -104.00%. Its return on capital employed (ROCE) is -61.40%.

Is COSM a good stock to buy?

This page provides a data-driven analysis of Cosmos Health Inc. (COSM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Cosmos Health Inc. COSM PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Why Did SOC, HTZ, COSM Stocks Tumble To 52-Week Lows? - Stocktwits

$8 million debt paid off. Cosmos Health bought back 5.1 million shares. - Stock Titan

$COSM stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

Why Did SOC, HTZ, COSM Stocks Tumble To 52-Week Lows? - finance.yahoo.com

Cosm | shares highlights from IPS and Ecsite 2026 - Blooloop

Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine - Fortune

COSM — Frequently Asked Questions

What is the current share price of Cosmos Health Inc. (COSM)?

What is the market capitalisation of COSM?

What is the P/E ratio of COSM?

What is the return on equity (ROE) of COSM?

Is COSM a good stock to buy?

Explore More